+1 Recommend
    • Review: found
    Is Open Access

    Review of 'Measures to minimize cross-contamination risks in Advanced Therapy Medicinal Product manufacturing'

    Measures to minimize cross-contamination risks in Advanced Therapy Medicinal Product manufacturingCrossref
    It is difficult to see what this paper adds to a previous publication from the same authors
    Average rating:
        Rated 2.5 of 5.
    Level of importance:
        Rated 2 of 5.
    Level of validity:
        Rated 2 of 5.
    Level of completeness:
        Rated 2 of 5.
    Level of comprehensibility:
        Rated 3 of 5.
    Competing interests:

    Reviewed article

    • Record: found
    • Abstract: found
    • Article: found
    Is Open Access

    Measures to minimize cross-contamination risks in Advanced Therapy Medicinal Product manufacturing

    Current European regulations define in vitro expanded cells for clinical purposes as substantially manipulated and include them in the class of Advanced Therapy Medicinal Products to be manufactured in compliance with current Good Manufacturing Practice. These quality requirements are generally thought to be elaborate and costly. However they ensure three main product characteristics: safety, consistency and absence of cross-contamination. The term cross-contamination is used to indicate misidentification of one cell line or culture by another. The Good Manufacturing Practice Guidelines suggest some recommendations in order to prevent cross-contaminations and require a demonstration that the implemented actions are effective. Here we report some practical examples useful both to minimize cross-contamination risks in an Advanced Therapy Medicinal Product production process and to evaluate the efficacy of the adopted measures.

      Review information

      This work has been published open access under Creative Commons Attribution License CC BY 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com.

      Autologous Chondrocyte Implantation,Good Manufacturing Practice,Cross-contamination,Advanced Therapy Medicinal Products,DNA Profiling

      Review text

      The paper certainly addresses a critical topic for cell based medicinal products. The title of the paper is very promising but the content does not meet the expectations. The introduction is correct but I would not agree to consider at the same level the three “main” characteristics described for an ATMP, i.e. "safety, consistency and absence of cross-contamination". Actually, cross-contamination is just one aspect of safety (as later described by the authors). The authors refer to the term cross-contamination “to indicate misidentification of one cell line or culture by another”. This is correct but it is not the only meaning of the term in the context of GMP (good manufacturing practice) and the measures described in the paper to avoid cross-contamination do mainly refer to other types of cross-contamination, i.e. microbiological contamination from the environment, personnel, raw materials or donors. This section of the paper is adequate but it is only a brief description of some of the requirements covered in GMP guidelines.

      Regarding the main part of the paper (How to prove the absence of cross-contamination in an ATMP) it is difficult to see what is new from their previous paper (references 10 and 11). However, the value of the technique they describe is acknowledged, also to ensure traceability throughout the production process and to the patient, another requirement for cell based medicinal products.

      Although the bibliography included in the paper is correct important specific references could have been added, i.e. Directive 2009/120/EC (where somatic cell therapy medicinal products are defined), or Annex 2 of the GMP guidelines (where there specific aspects for ATMP are described).


      Comment on this review